You have come to the Abstract Submission and Guidelines page for the annual Summit4CI taking place October 1st – 4th, 2023 in Ottawa, Ontario.

Submit your abstract

Scientific Abstract Instructions

Scientific abstracts must be 250 words or fewer. For more information and to upload please proceed to the abstract submission page. Note, all Summit registrants are eligible to submit an abstract. For questions about scientific fit to the Summit4CI, please contact Sarah Ivanco at [email protected]. BioCanRx will review all abstracts and authors will be notified of their acceptance in August 2023. Please note HQP Travel Award-specific instructions and timelines below.

HQP Travel Awards and Invited Talks

This year, BioCanRx will be providing travel support (up to $1,200 CAD) for up to 100 HQP to attend the Summit4CI. Highly qualified personnel (HQP) are defined as undergraduates, graduate students, postdoctoral fellows and other positions integral for the translation of cancer biotherapeutics working in an academic setting. Individuals working in positions eligible to receive CIHR funding in an investigator (not trainee) capacity are ineligible to receive HQP Travel Awards. Travel awards will be adjudicated based on the quality of abstracts. The authors of the top-ranked abstracts will be invited to present an oral presentation during the oral plenary or a speed poster presentation (as well as poster sessions). Other awardees will be presenting during the poster sessions. Trainee talks and posters that are submitted by this travel award deadline will be adjudicated at the Summit4CI, and top trainee authors will receive an award.

We cannot guarantee that you will be selected for a travel award to the Summit4CI, however we will inform all submitters of the success in the travel award competition 1 week prior to the Summit’s early bird registration deadline.

Plain Language Abstracts (optional for HQP only)

Following from the success at last year’s Summit4CI, we are again inviting HQP to submit a plain language summary abstract. The BioCanRx Cancer Stakeholder Alliance (CSA) Working Group will be reviewing plain language abstracts, and selecting up to 50 submissions. These 50 HQP will be invited to deliver their plain language presentations during the poster session for judging by the CSA working group. The top presenter will be awarded a prize given on behalf of the CSA. Please note, presenters will be using the same poster as for their scientific presentations.

Plain language abstracts must be 130 words or fewer. Plain language summaries of your research are targeted to our patient groups and other non-academic members attending the Summit4CI. To facilitate writing this document, we recommend you refer to our plain language summary guide: https://www.bcahsn.ca/learning/plain-language-guide.

You can also check out our webinar with Dr. Barbara Vanderhyden on Science Communication 101 here.

Abstract Submission Deadline & Other Key Dates
Please note all deadlines are at 11:59 PM Pacific Time.

Abstract submission deadline to be considered for a Travel Award (HQP only)
Notifications of travel award success
Final Abstract submission deadline
Notifications of abstract submission success


Please note that the number of poster spots is limited.
Poster spots will only be reserved for abstracts that are submitted before the abstract submission deadline of August 1st, 2023, and/or are selected for a poster presentation by the Summit4CI Abstract Review Board. Award of all poster spots will be determined by the Summit4CI Abstract Review Board and is subject to availability of space.

For Poster Guidelines, Click Here